Table 3. Univariate and multivariate analyses of factors associated with survival and recurrence.
| factor | Overall survival | Cumulative Recurrence | ||||||
| Univariate | Multivariate | Univariate | Multivariate | |||||
| P | HR | 95% CI | P | P | HR | 95% CI | P | |
| Sex (male versus female) | 0.835 | NA | 0.487 | NA | ||||
| Age (<52 versus >52 years) | 0.234 | NA | 0.641 | NA | ||||
| HBsAg (negative versus positive) | 0.563 | NA | 0.215 | NA | ||||
| Child-Pugh score (A versus B) | 0.637 | NA | 0.626 | NA | ||||
| Serum AFP (>20 versus <20 ng/mL) | 0.037 | 1.335 | 0.978–1.822 | NS | 0.379 | NA | ||
| Tumor size (>5 versus <5 cm) | 0.002 | 1.378 | 1.006–1.887 | 0.046 | 0.114 | NA | ||
| Tumor number (multiple versus single) | 0.003 | 1.637 | 1.098–2.440 | 0.015 | 0.083 | NA | ||
| Microvascular invasion (yes versus no) | <0.001 | 1.886 | 1.114–3.191 | 0.018 | 0.018 | 1.917 | 1.053–3.488 | 0.033 |
| Tumor encapsulation (none versus complete) | 0.002 | 1.323 | 0.952–1.841 | NS | 0.087 | NA | ||
| Tumor differentiation (III/IV versus I/II) | 0.018 | 1.365 | 0.989–1.884 | NS | 0.061 | NA | ||
| TNM stage (I/II versus III) | <0.001 | NA | 0.001 | NA | ||||
| CD151 density (<50% versus >50%) | 0.002 | 0.698 | 0.512–0.951 | 0.023 | <0.001 | 0.555 | 0.396–0.777 | 0.001 |
| Integrin β1 density (high versus low) | 0.153 | NA | 0.054 | NA | ||||
| CD151/ Integrin β1 density* | 0.002 | 0.003 | <0.001 | <0.001 | ||||
| I verse II | 1.571 | 1.091–2.262 | 0.015 | 2.028 | 1.366–3.013 | <0.001 | ||
| I verse III | 0.847 | 0.515–1.392 | NS | 0.860 | 0.491–1.506 | NS | ||
| I verse IV | 0.718 | 0.438–1.174 | NS | 0.646 | 0.380–1.096 | NS | ||
The Cox proportional hazards regression model was used.
Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; HBsAg, hepatitis B surface antigen; HR, hazard ratio; NA, not adopted; NS, not significant.
*Patients were classified into four groups according to their CD151 and Integrin β1 density: group I (n = 93) had high expression of CD151 and Integrin β1, group II (n = 47) had high expression of CD151 but low Integrin β1 expression, group III (n = 58) had high expression of Integrin β1 but low CD151 expression and group I V (n = 103) had low expression of CD151 and Integrin β1. Individual variables were first adopted for their prognostic significance by multivariate analysis, and then the combination of CD151 and Integrin β1 was analyzed.